特斯拉(TSLA.US)英國和德國上月銷量下降超過55%
特斯拉(TSLA.US)在歐洲市場持續低迷,最新數據顯示,特斯拉7月於英國和德國的新車銷量均大跌逾五成。
英國汽車製造商與貿易商協會公佈,特斯拉上月在英國僅售出987部新車,按年大減近60%,去年同期賣出2,462部。德國方面,聯邦機動車交通局稱,特斯拉7月銷量按年減少55%至1,110部,今年首七個月累共賣出10,000部,按年大減57.8%。
同時,內地電動車品牌比亞迪則在英德兩地實現爆發式增長。該公司上月在英國售出3,184部車輛,按年大增四倍以上;在德國銷售亦按年增近390%,成爲歐洲市場中表現最亮眼的電動車製造商之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.